KALV - Company ID 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q2 2025 | Q1 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.46M | -$54.50M | -$47.57M | -$40.22M | -$26.73M | -$22.74M |
| Capital expenditure | $121.00K | $290.00K | $288.00K | $21.00K | $6.00K | $920.00K |
| Investing cash flow | -$901.00K | $21.26M | -$3.72M | $37.16M | $19.61M | $30.04M |
| Dividends paid | - | - | - |
KalVista Pharmaceuticals, Inc. reported operating cash flow of -$152.91M for fiscal year 2025. That is down 71.4% from -$89.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$13.16M (FY 2016) to -$152.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.47M | $23.21M | $2.22M | $3.00M | $204.00K | $168.00K |